Edition:
United States

Revance Therapeutics Inc (RVNC.OQ)

RVNC.OQ on NASDAQ Stock Exchange Global Market

28.35USD
4:00pm EDT
Change (% chg)

$-1.10 (-3.74%)
Prev Close
$29.45
Open
$29.45
Day's High
$29.80
Day's Low
$28.25
Volume
76,708
Avg. Vol
96,552
52-wk High
$37.45
52-wk Low
$18.42

Chart for

About

Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $1,087.29
Shares Outstanding(Mil.): 36.73
Dividend: --
Yield (%): --

Financials

  RVNC.OQ Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -4.00 -- --
ROI: -52.49 -0.73 12.97
ROE: -54.09 -2.77 14.84

Mylan teams up with Revance on biosimilar for Botox

NEW YORK Mylan NV on Wednesday struck a licensing agreement with Revance Therapeutics Inc to develop a biosimilar of Allergan Plc's blockbuster Botox wrinkle treatment.

Feb 28 2018

CORRECTED-Mylan teams up with Revance on biosimilar for Botox

NEW YORK, Feb 28 Mylan NV on Wednesday struck a licensing agreement with Revance Therapeutics Inc to develop a biosimilar of Allergan Plc's blockbuster Botox wrinkle treatment.

Feb 28 2018

BRIEF-Revance Reports Qtrly Net Loss Per Share Attributable To Common Stockholders $1.14

* REVANCE THERAPEUTICS INC - ‍REITERATES ITS FINANCIAL GUIDANCE PROVIDED IN JANUARY 2018​

Feb 28 2018

BRIEF-Revance Therapeutics, Mylan Ireland Enter Collaboration Deal‍

* REVANCE THERAPEUTICS SAYS ‍CO, MYLAN IRELAND LIMITED ENTERED INTO COLLABORATION DEAL- SEC FILING​

Feb 28 2018

BRIEF-Revance Therapeutics Inc Announced Interim 8-Week Phase 2A Results For Rt002 In Treating Plantar Fasciitis

* REVANCE THERAPEUTICS INC - ANNOUNCED INTERIM 8-WEEK PHASE 2A RESULTS FOR RT002 IN TREATING PLANTAR FASCIITIS

Jan 08 2018

BRIEF-Revance Provides Update On Anticipated Clinical Milestones And Financial Outlook For 2018

* REVANCE PROVIDES UPDATE ON ANTICIPATED CLINICAL MILESTONES AND FINANCIAL OUTLOOK FOR 2018

Jan 04 2018

Revance will wait to seek backing for Botox-rival

Revance Therapeutics Inc will wait to seek partnerships with bigger drugmakers until it is closer to regulatory approval for its Botox rival treatment, Chief Executive Dan Browne told Reuters in an interview.

Dec 13 2017

BRIEF-Revance Announces Pricing Of Public Offering Of Common Stock

* REVANCE ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Dec 07 2017

BRIEF-Revance Therapeutics Files For Potential Mixed Shelf Offering ‍​‍​

* REVANCE THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING ‍​‍​ Source text: (http://bit.ly/2nwJNaw) Further company coverage:

Dec 05 2017

BRIEF-Revance Announces Proposed Public Offering Of Common Stock

* REVANCE THERAPEUTICS INC - PROPOSED UNDERWRITTEN PUBLIC OFFERING IN WHICH IT WILL ISSUE AND SELL APPROXIMATELY $175 MILLION OF SHARES OF ITS COMMON STOCK

Dec 05 2017

Earnings vs. Estimates